inflammatori
bowel
diseas
ibd
includ
crohn
diseas
cd
ulcer
coliti
uc
chronic
intestin
inflammatori
condit
might
caus
environment
genet
immunolog
imbal
clinic
treatment
diseas
limit
ineffici
develop
novel
therapeut
strategi
ibd
enorm
research
focus
explor
detail
mechan
ibd
pathophysiolog
anim
model
includ
trinitrobenzen
sulfon
acid
tnb
induc
experiment
coliti
dextran
sulfat
salt
dss
induc
coliti
number
genet
mous
model
establish
studi
underli
mechan
well
accept
dysregul
immun
respons
play
critic
role
coliti
tumor
necrosi
wellstudi
cytokin
implic
patholog
progress
human
ibd
inhibit
activ
antibodi
wide
use
clinic
treatment
ibd
studi
also
indic
profound
role
axi
pathogenesi
ibd
therefor
immun
suppress
drug
inhibit
effector
cell
immun
respons
promot
treg
expans
also
use
ibd
patient
howev
patient
exhibit
effect
respons
therapi
addit
seriou
side
effect
includ
infect
anaphylaxi
malign
observ
treatment
therefor
altern
therapeut
imper
treatment
ibd
glucagonlik
peptid
glp
includ
secret
endocrin
cell
gut
nutrient
uptak
stimul
islet
cell
secret
insulin
inhibit
gastric
empti
reduc
food
ingest
play
crucial
role
lower
blood
glucos
control
bodi
weight
therefor
use
human
subject
type
diabet
especi
obes
patient
type
diabet
contrast
use
therapi
intestin
injuri
short
bowel
syndrom
due
effect
promot
mucos
epithelium
expans
crypt
cell
prolifer
improv
intestin
adapt
nutrient
absorpt
glp
degrad
dipeptidyl
quickli
result
short
halfliv
minut
vivo
inhibitor
recent
gain
increas
attent
role
incretin
hormon
bowel
diseas
demonstr
recent
dssinduc
coliti
sever
intestin
injuri
increas
mice
consist
administr
led
signific
improv
anim
weight
loss
intestin
inflamm
mice
spontan
coliti
mous
model
discuss
indepth
action
axi
ibd
glucagonlik
exert
pleiotrop
function
bind
receptor
involv
develop
progress
mani
diseas
receptor
wide
express
mani
organ
tissu
includ
endocrin
pancrea
gastrointestin
tract
heart
central
nervou
system
recent
work
shown
defect
cellular
respons
akin
insulin
resist
combin
diminish
predomin
role
pathogenesi
patient
exogen
administr
pharmacolog
dose
receptor
agonist
shown
restor
sensit
insulin
induc
secret
insulin
impair
incretin
respons
associ
insulin
resist
nondiabet
diabet
individu
first
two
aminoacid
residu
nterminu
caus
suscept
degrad
ntermin
residu
rapidli
cleav
express
surround
tissu
result
inactiv
exenatid
liraglutid
dulaglutid
albiglutid
lixisenatid
structur
modifi
analog
use
clinic
set
exhibit
rel
resist
cleavag
longcircul
halflif
exogen
administr
potent
inhibit
gastric
empti
rodent
human
studi
favor
bodi
weight
loss
diabet
patient
prone
develop
cardiac
disord
action
cardiac
function
investig
sinc
receptor
wide
express
brain
role
central
nervou
system
beyond
regulatori
function
glycem
control
explor
expectedli
possess
protect
effect
neuron
damag
reduc
iboten
acidinduc
deplet
cholin
acetyltransferas
immunoreact
receptordefici
mice
shown
defect
cognit
function
synapt
plastic
memori
format
recov
transfer
gene
hippocampu
data
reveal
may
pleiotrop
function
multitud
diseas
action
ibd
discuss
glucagonlik
aminoacid
peptid
cleav
rodent
human
halflif
slightli
longer
unlik
play
role
glucos
homeostasi
primarili
exert
potenti
effect
intestin
weight
gain
mucos
develop
intestin
integr
view
abovement
effect
treatment
reduc
intestin
inflamm
improv
intestin
heal
injuri
addit
benefit
improv
intestin
integr
also
exhibit
antimicrobi
effect
regul
synthesi
activ
paneth
cellproduc
antimicrobi
peptid
addit
reduc
bacteri
invas
promot
secretori
immunoglobulin
iga
express
receptor
wide
express
mani
tissu
cell
physiolog
effect
beyond
gut
also
report
like
also
regul
function
central
nervou
system
activ
receptor
reduc
stressinduc
depress
improv
memori
anim
experi
also
play
substanti
role
bone
metabol
via
reduc
bone
reabsorpt
improv
bone
miner
densiti
shown
improv
liver
regener
enhanc
lung
recoveri
mice
thu
reveal
potenti
effect
gastrointestin
tract
recent
studi
demonstr
glp
exert
inflamm
regulatori
function
metabol
diseas
administr
markedli
reduc
macrophag
infiltr
product
inflammatori
cytokin
adipos
tissu
obob
mice
also
shown
regul
invari
natur
killer
cell
inkt
macrophag
function
human
anim
studi
carri
mice
suggest
may
play
role
maintain
peripher
treg
number
suppress
lymphocyt
hyperprolifer
although
also
blunt
inflammatori
cytokin
product
via
inhibit
activ
erk
phosphoryl
enhanc
macrophag
accumul
observ
colon
colit
mice
recent
studi
report
control
gut
immun
regul
intestin
intraepitheli
lymphocyt
function
lead
protect
role
dssinduc
coliti
consist
treatment
also
reduc
proinflammatori
cytokin
protein
level
mous
model
coliti
taken
togeth
glp
play
crucial
role
inflamm
regul
gut
disord
dipeptidyl
typeii
integr
transmembran
glycoprotein
best
known
catalyt
function
solubl
form
lack
cytoplasm
transmembran
domain
preserv
catalyt
activ
also
detect
plasma
although
mechan
regul
express
remain
unclear
implic
primari
substrat
enterocrinin
gip
respons
glucos
metabol
genedefici
mice
show
improv
postprandi
glucos
control
resist
progress
obes
hyperinsulinemia
inhibit
enzymat
activ
pharmacolog
agent
administr
improv
glucos
toler
wildtyp
mice
knockout
mice
addit
enterocrinin
chemokin
cytokin
could
also
cleav
stromal
cellderiv
also
known
gcsf
gmcsf
erythropoietin
therebi
allow
regul
immun
respons
also
exert
noncatalyt
function
via
interact
adenosin
deaminas
ada
fibronectin
bestknown
noncatalyt
function
interact
ada
act
costimulatori
dyad
promot
tcell
activ
previou
work
demonstr
role
nonenzymat
function
regul
dendrit
cell
dc
macrophagemedi
adipos
tissu
inflamm
obes
also
show
longterm
inhibit
reduc
atherosclerosi
inflamm
via
effect
macrophag
migrat
furthermor
nonobes
diabet
nod
mice
inhibitor
significantli
increas
level
treg
expans
beyond
recent
studi
well
other
demonstr
play
role
infect
middl
eastern
respiratori
syndrom
mer
viru
bplower
antiatherosclerot
effect
agonist
well
demonstr
gastrointestin
effect
glp
underappreci
discuss
relationship
inflamm
gastrointestin
tract
uc
patient
colectomi
show
slower
releas
respons
intak
glucos
consist
postprandi
respons
also
impair
patient
ileostomi
yet
known
whether
colectomi
inflammatori
state
affect
releas
ibd
subsequ
studi
demonstr
although
mrna
level
reduc
sampl
harvest
inflam
site
ibd
patient
coliti
mice
level
increas
sera
ibd
patient
compar
healthi
control
defect
releas
ibd
patient
colectomi
might
caus
loss
colon
endocrin
tissu
therefor
data
reveal
link
gut
inflamm
express
bring
emerg
question
implic
ibd
explor
question
studi
conduct
experiment
anim
coliti
tcell
adopt
transferinduc
coliti
express
colon
tissu
significantli
diminish
scid
mice
adopt
transfer
cell
compar
control
mice
furthermor
dssinduc
coliti
consider
increas
detect
colit
mice
inhibitor
treatment
notwithstand
alter
express
coliti
exact
role
develop
coliti
remain
unknown
term
benefici
detriment
recent
studi
show
analog
liraglutid
exert
signific
improv
diseas
activ
endpoint
includ
colon
tissu
histolog
chang
colon
weightlength
ratio
might
due
role
reduc
inflammatori
cytokin
chemokin
chemokin
motif
ligand
previous
establish
key
chemokin
cell
repres
cytokin
immun
respons
respect
line
result
steric
stabil
phospholipid
micel
show
long
halflif
resist
markedli
allevi
develop
dssinduc
mice
coliti
reduc
express
proinflammatori
cytokin
moreov
intestin
epitheli
architectur
coliti
model
administr
significantli
improv
conclus
might
act
novel
therapeut
tool
amelior
colon
inflamm
regard
inhibit
enterocyt
apoptosi
stimul
crypt
cell
prolifer
thought
associ
tissu
repair
injuri
infect
therefor
chemic
induc
enter
vascularischemia
reperfus
injuri
show
protect
effect
base
reduc
epitheli
barrier
damag
lower
bacteri
infect
stand
reason
might
potenti
therapeut
target
ibd
condit
character
destruct
gastrointestin
epithelium
adopt
tcell
transfer
model
coliti
amount
colon
tissu
also
decreas
compar
normal
mice
scid
mice
without
tcell
adopt
transfer
howev
result
duplic
human
ibd
sampl
studi
show
chang
level
fast
plasma
ibd
patient
control
pinpoint
lcell
secret
alter
pathogenesi
ibd
nevertheless
circul
level
bioactiv
markedli
increas
cd
uc
patient
alter
might
due
adopt
respons
intestin
injuri
promot
mucos
epithelium
restor
selfrepair
mechan
discrep
data
might
causal
agent
differ
inflammatori
condit
increas
l
cell
found
remiss
statu
coliti
anoth
reason
probabl
due
detect
reagent
detect
bioactiv
beyond
promot
crypt
cell
prolifer
mucos
integr
also
exert
distinct
role
antiinflammatori
action
mimic
antiinflammatori
therapeut
approach
human
combin
aminosalicyl
asa
corticosteroid
administr
mice
dssinduc
coliti
synergist
effect
observ
interestingli
corticosteroid
administr
prevent
intestin
weight
increas
mice
treat
corticosteroid
treatment
exhibit
similar
antiinflammatori
effect
colon
tissu
howev
tnbsinduc
ileiti
dssinduc
coliti
treatment
downregul
express
inflammatori
cytokin
includ
antiinflammatori
cytokin
increas
anoth
report
also
show
allevi
develop
coliti
reduc
proinflammatori
cytokin
mous
model
level
induc
nitric
oxid
synthas
ino
marker
classic
activ
macrophag
reduc
mice
suggest
might
alter
macrophag
polar
noteworthi
chronic
coliti
risk
factor
colon
cancer
interestingli
report
shown
exogen
endogen
potenti
cancer
promot
mice
model
although
reduc
inflamm
also
observ
might
result
strong
prefer
epithelium
prolifer
therefor
surveil
dysplasia
colon
cancer
must
vigil
treatment
regard
catalyt
function
previou
studi
demonstr
act
immun
regul
via
express
immun
cell
abil
cleav
biolog
activ
chemokin
cytokin
henc
involv
pathogenesi
coliti
propos
involv
might
depend
two
major
pathway
catalyt
function
noncatalyt
function
like
inhibitor
prolif
effect
colon
epithelium
also
demonstr
protect
effect
inhibitor
ibd
might
result
increas
level
notabl
plasma
level
increas
respons
inhibitor
thu
effect
epithelium
expans
induc
inhibitor
probabl
reli
indirect
elev
express
investig
influenc
pathogenesi
dssinduc
coliti
mice
use
dss
treatment
increas
myeloperoxidas
mpo
activ
express
subunit
colon
tissu
observ
furthermor
increas
percentag
splenic
cell
nkt
cell
mice
observ
keep
mice
mice
also
show
signific
increas
macrophag
compar
wildtyp
mice
data
reveal
detriment
role
develop
coliti
convers
rat
reveal
appar
diminish
diseas
activ
index
dai
lowdos
dssinduc
coliti
especi
dssinduc
coliti
similar
effect
also
investig
inhibitor
anagliptin
mice
dssinduc
coliti
addit
anagliptin
administr
amelior
bodi
weight
loss
dai
addit
significantli
lower
histolog
score
observ
anagliptintr
group
suggest
inhibit
activ
facilit
resolut
mucos
damag
taken
togeth
find
suggest
complex
dichotom
biolog
develop
ibd
might
due
multifunct
due
vital
role
glp
intestin
heal
antiinflammatori
function
sound
understand
product
regul
function
glp
degrad
enzym
facilit
treatment
coliti
potenti
mechan
figur
axi
ibd
may
includ
follow
glp
promot
tissu
repair
injur
epithelium
glp
regul
tcell
differenti
function
eg
treg
effector
cell
intraepitheli
lymphocyt
glp
regul
function
innat
immun
cell
macrophag
dc
suppress
enzymat
activ
pharmacolog
inhibitor
preserv
glp
function
although
studi
area
mainli
carri
anim
model
limit
clinic
trial
phaseii
clinic
trial
teduglutid
analog
observ
remiss
rate
cd
patient
extent
glp
contribut
ibd
human
requir
investig
ld
xr
review
literatur
wrote
first
draft
zb
jz
review
literatur
final
manuscript
author
read
approv
final
manuscript
jz
current
receiv
grant
boehring
ingelheim
remain
author
conflict
interest
